Key Highlights
- The option allows employers to contribute toward the cost of FDA-approved GLP-1 medications outside traditional pharmacy benefit designs.
- Employers pay a fixed amount per employee per fill, and employees pay the remaining balance for each fill.
- Teladoc said medications from both Eli Lilly and Novo Nordisk can be offered through the program.
- According to WTW, nearly half of employers do not currently cover GLP-1s for weight loss.
Teladoc Health (NYSE:TDOC), a virtual care provider, announced an expansion of its Comprehensive Weight Care program that gives employers a new option for providing access to GLP-1 medications. The option allows employers to contribute toward the cost of medications outside traditional pharmacy benefit structures, while keeping employee out-of-pocket costs flexible.
The company said the change responds to high Demand for GLP-1 medications and to a gap in coverage, noting that nearly half of employers currently do not cover GLP-1s for weight loss, based on WTW data.
The program’s clinical team includes obesity medicine clinicians, registered dietitians and health coaches, and the company describes ongoing care as a central element of the offering rather than a one-time prescription.
How the Employer Contribution Model Works
Employers manage the program through a single contract with Teladoc for both the clinical program and medication access. Each plan year, the employer sets a fixed payment per employee per Fill that applies consistently across covered medications, and employees pay the balance for each fill.
Teladoc manages eligibility, program oversight and consolidated employer invoicing. Pharmacy claims are administered on a 100% pass-through basis, with real-time application of each employer’s payment. Employers see the cost of each fill broken into the medication, pharmacy dispensing fee and claims administration fee.
The employer option operates outside traditional pharmacy benefit designs, which gives employers a separate route for funding medication costs alongside their existing plans.
Employers see the cost of each fill in a breakdown, which the company said makes benefit spending easier to track against plan budgets.
Medication Access and Clinical Services
Through the offering, employers can provide access to medications from Eli Lilly and Novo Nordisk, both of which are cited in the announcement as partners. The company said the medications are authentic, FDA-approved products.
The clinical component includes licensed obesity medicine clinicians, registered dietitians and health coaches, along with connected digital scales, lifestyle coaching, nutrition counseling, AI-enabled food logging, mental health support and behavior-change resources. The company said the care team stays with members over time.
Members receive the program’s care team on an ongoing basis, with support designed to address obesity care over time. The release describes ongoing support as a central part of the offering.
Partner Statements and Employer Context
Kelly Bliss, president of U.S. Group Health at Teladoc, said employers need flexible strategies that work for their organizations and that the company aims to give people a path to high-quality care. Kevin Hern, senior vice president at Lilly USA, said Lilly Employer Connect gives employers greater choice, control and cost transparency.
Tom Scales, senior vice president of market access and public affairs at Novo Nordisk, said the company works with approved collaborators such as Teladoc to provide employer-funded access pathways. The statements from both drugmakers position the option as a way for employers to manage predictable costs.
The release presents the option as a response to employer demand for predictable spending and transparency, with both drugmakers describing their own employer access efforts in similar terms.
Final Word
Teladoc’s expanded program gives employers a fixed per-fill payment option for GLP-1 medications from two manufacturers, bundled with clinical care and lifestyle support. The company said pharmacy claims are administered on a pass-through basis, with each employer seeing the components of every fill.
The announcement does not disclose the pricing of the payment structure, the number of employers enrolled or any Revenue expectations. Enrollment and coverage data will indicate how the option is adopted across employer benefit plans.


_11_20_2026_20_27_34_097200.jpg)



Please wait processing your request...